ADCs in Development for the Treatment of Lung Cancer


Drs Martin Dietrich and Wade Thomas Iams discuss the differences between the targets, payloads, and linker technologies of the antibody drug conjugates in development for lung cancer.

Related Videos
Alessandro Di Federico, MD
Expert on SCLC
Dazhi Liu, PharmD, MS, BCOP
Stephen V. Liu, MD
Sanam Loghavi, MD
Experts on lung cancer
Luis Raez, MD, an expert on lung cancer
Jia Luo, MD
Expert on SCLC
Experts on SCLC
Related Content